|
 |
Acyclovir medication is used to
treat herpes infections of the skin, mouth, mucous membranes, genital
herpes, herpes zoster (shingles), and chickenpox in some individuals. This
medication does not cure herpes, but relieves the pain and may make the
infection clear faster. |
|
Acyclovir 200mg (30 pills) |
|
 |
|
Acyclovir 200mg (90 pills) |
|
|
|
Acyclovir 400mg (30 pills) |
|
|
|
Acyclovir 400mg (90 pills) |
|
|
|
Acyclovir 800mg (30 pills) |
|
|
|
Acyclovir 800mg (90 pills) |
|
|
Prescription Drug Acyclovir Side
Effects:
Acyclovir medication
800 mg may cause stomach
upset, loss of appetite, nausea, vomiting, diarrhea, headache,
dizziness or weakness. These effects should disappear in a few
days as your body adjusts to the medication. If they persist or
become worse, inform your doctor. Notify your doctor if you
experience: numbness or tingling of the hands or feet, leg pain,
sore throat, skin rash, change in the amount of urine. An
allergic reaction to this drug is unlikely, but seek immediate
medical attention if it occurs. Symptoms of an allergic reaction
include: rash, itching, swelling, dizziness, trouble breathing.
If you notice other effects not listed above, contact your doctor
or pharmacist
Precautions on using Acyclovir
prescription:
Acyclovir medication should be
used cautiously during pregnancy only if clearly needed. It is
not known if this medication appears in breast milk. Consult with
your doctor before breast-feeding.
Acyclovir Drug Interaction:
Inform your doctor about all the
medicines you use (both prescription and nonprescription). Do not
start or stop any medicine without doctor or pharmacist approval.
MedWorm: Acyclovir / Zovirax
|
Effect of prophylactic oral acyclovir after penetrating keratoplasty for herpes simplex keratitis.
|
|
Page: 930DOI: 10.1097/ICO.0b013e3180e79b77Authors: Garcia, Denise D MD *; Farjo, Qais MD +; Musch, David C PhD ++; Sugar, Alan MD ++ (Source: Cornea)
|
|
Acyclovir(acyclovir) suspension [actavis mid atlantic llc]
|
|
Updated Date: Aug 24, 2007 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
|
|
Usmle forum :: you are taking care of a 49-year-old woman who was admi.,..
|
|
Author: skinyballs
Subject: You are taking care of a 49-year-old woman who was admi.,..
Posted: Fri Aug 17, 2007 9:51 am (GMT -5)
Topic Replies: 0
You are taking care of a 49-year-old woman who was admitted to the hospital because of progressive numbness of the right arm and difficulty in seeing objects in the left visual field. She is known to be HIV positive, but has not consistently taken medications in the past. On examination she is healthy appearing, has a right homonymous hemianopia, and decreased sensory perception in her left upper extremity and face. Her CD4 count is 60 cells/mm3 and her MRI is consistent with a demyelinating lesion of the left parietooccipital area. CSF PCR for the JC virus is positive. The most appropriate
treatment is
A. amphotericin B
B. cranial radiation
C. highly active antiretroviral therapy (HAART)
D. intravenous acyclovir
E. intravenous ceftriaxone
I FOUND FREE QUESTIONS AT:
www.usmlepack.blogspot.com (Source: Med Student Guide)
|
|
Oral antivirals effective for prophylaxis against recurrent genital herpes
|
|
According to the results of a meta-analysis published in the Journal of the American Academy of Dermatology, oral aciclovir, valaciclovir, and famciclovir are highly effective as prophylaxis against recurrent genital herpes. The authors note that symptomatic recurrent flares are common in patients who have anti-herpes simplex virus (HSV) antibodies, with a median of four recurrences during the first year following the initial episode. Because recurrences are associated with major medical and psychosocial morbidities, and due to the potential sexual health risks, suppressive therapy is required, particularly in those with frequent and/or severe episodes.
In this review, the authors sought to compare the clinical efficacy of acyclovir (ACV), valaciclovir (VCV) and famciclovir (FCV) for the suppression of recurrent genital herpes. They carried out a search of the literature (MEDLINE and EMBASE) and identified 14 parallel RCTs (n=6,158) comparing oral antivirals to placebo for the prophylaxis of recurrent genital herpes in immunocompetent individuals, that met the inclusion criteria. The main endpoint was the number of patients developing at least one genital herpes recurrence during the trial. The main findings were:
• Antivirals reduced the risk of having at least one recurrent episode during the study period compared to placebo (overall RR 0.533; p<0.001), with a NNT of 2.15 (95% CI 2.06-2.25). The trials were found to be significantly heterogenous [the pooled results should therefore be interpreted with extreme caution; however all trials showed that the antiviral in question was statistically significantly superior to placebo].
• For individual agents, the results were: ACV (10 trials) - RR 0.467 (0.43-0.49; p<0.001); FCV (2 trials) – RR 0.576 (0.50-0.65; p<0.001), and VCV (3 trials) – RR 0.568 (0.53-0.59; p<0.001). Again, there was significant heterogeneity between the sub-groups.
• The best evaluated regimens, with comparable efficacies, were given twice daily, ie, acyclovir (400 mg twice daily), VCV (250 mg twice daily), and FCV (250 mg twice daily), or once daily (VCV 500 mg).
The authors note various limitations to their study, including the short follow-up and hetergogeneity of the included studies. In addition, the only endpoint available for all the studies was the number of patients presenting at least one recurrence of genital herpes during the observation period. (Source: NeLM Headline News)
|
|
|
|
|
